Mission Therapeutics will receive a $20million milestone payment from AbbVie after two targets progressed to the next stage of drug discovery in their neurodegenerative disease collaboration.
The Babraham Research Campus company is working with global biopharmaceutical firm to identify novel deubiquitylating enzyme (DUB) targets and discover associated inhibitor compounds.
The selection of two targets follows promising data from in vitro and in vivo Alzheimer’s and Parkinson’s disease models.
Both these diseases are associated with the accumulation of misfolded proteins in the brain.
DUBs help to maintain cell health by regulating the degradation of proteins.Read the full article here